Randomised phase-III-study of the multi-kinase inhibitors Sorafenib (BAY 43-9006) for patients with advanced renal cell carcinoma

被引：0
|
作者：
Staehler, M. [1 ]
Siebels, M. [2 ]
Stief, C. [1 ]
Jaeger, E.
Heinzer, H.
Grimm, M. -O.
Gschwend, J.
Wirth, M.
Michell, M. -S.
Rohde, D.
Krause, S.
Siegsmund, M.
Scheuring, U.
Schwartz, B.
Escudier, B.
机构：
[1] Univ Munich, Klin Grosshadern Ludwig Maximilians, Munich, Germany
[2] Urol Gemeinschaftspraxis Pasing, Munich, Germany
来源：
ONKOLOGE | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [21] A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC)
    Chen, E.
    Winquist, E.
    Agulnik, M.
    Chin, S.
    Pond, G.
    Cheiken, R.
    Francis, P.
    Petrenciuc, O.
    Siu, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 297 - 297
  • [22] A phase I study of sorafenib (BAY 43-9006) in combination with S-1 plus cisplatin in patients with advanced gastric cancer
    Yamada, Yasuhide
    Minami, Hironobu
    Fuse, Nozomu
    Ohtsu, Atsushi
    Kato, Ken
    Kiyota, Naomi
    Shimada, Yasushiro
    Doi, Toshihiko
    Nakajima, Takako
    Hamaguchi, Tetsuya
    Fujiwara, Yutaka
    Ito, Yuichiro
    Mera, Kiyomi
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [23] Prospective study of positron emission tomography evaluating the activity of sorafenib (BAY 43-9006) in patients with advanced tumors.
    Kawada, K
    Murakami, K
    Sato, T
    Kojima, Y
    Ebi, H
    Kitagawa, K
    Kim, Y
    Araki, K
    Mukai, H
    Tahara, M
    Nakajima, H
    Nakajima, K
    Minami, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9062S - 9062S
  • [24] Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma
    Eisen, T.
    Ahmad, T.
    Marais, R.
    Gibbens, I.
    James, M.
    Affolter, A.
    Chao, D.
    Bergamini, L.
    Schwartz, B.
    Gore, M. E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 349 - 349
  • [25] A Phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer
    Bianchi, G.
    Loibl, S.
    Zamagni, C.
    Ardizzoni, A.
    Raab, G.
    Siena, S.
    Wolf, C.
    Westermeier, T.
    Bergamini, L.
    Gianni, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 78 - 78
  • [26] Phase II study of BAY 43-9006 (sorafenib) in patients with chemo-naive hormone refractory prostate cancer
    Akyol, F.
    Ozyigit, G.
    Selek, U.
    Onal, C.
    Karabulut, E.
    Ozen, H.
    EJC SUPPLEMENTS, 2005, 3 (02): : 248 - 249
  • [27] Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor
    Massard, Christophe
    Zonierek, J.
    Laplanche, A.
    Schwartz, Brian
    Szczylik, Cezary
    Escudier, Bernard
    ANNALS OF ONCOLOGY, 2006, 17 : 148 - 149
  • [28] Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors
    Steinbild, S
    Baas, F
    Gmehling, D
    Brendel, E
    Christensen, O
    Schwartz, B
    Mross, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 220S - 220S
  • [29] A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid cancers.
    Awada, A
    Hendlisz, A
    Gil, T
    Bleiberg, H
    Bartholomeus, S
    De Valeriola, D
    Dewitte, M
    Coppieters, S
    Moeller, J
    De Becker, D
    Meert, A
    Piccart, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [30] Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients.
    Eisen, T
    Ahmad, T
    Gore, ME
    Marais, R
    Gibbens, I
    James, MG
    Schwartz, B
    Bergamini, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 712S - 712S
12345